Dissolvable / Biodegradable Double‑J Ureteral Stents

Comprehensive evidence brief for endourology — materials, latest trials, complications, surgical utility, and roadmap to clinical adoption.

Prepared for: Dr. Ahmad Hamad Alghurair, Urology Specialist Compiled on · July 10, 2026 Sources: PubMed/MEDLINE + Frontiers + PMC Uptake: Rapid uptick 2024–2026
~50
Papers identified
5
Major reviews 2024–26
2
Key EAU/experimental RCT cohorts (2026)
40+
Years of R&D (1983 → 2026)

Overview Background

The clinical problem

Standard polymeric Double J stents were a 1978 paradigm shift, but 40+ years later they remain imperfect: encrustation in forgotten stents, cystoscopy removal under GA, bacteruria, flank pain, bypass obstructions, and socioeconomic cost. Biodegradable/dissolvable ureteral stents (BUS) aim to eliminate the removal procedure entirely and reduce biofilm/encrustation by continuous surface renewal as the matrix degrades.

Why now?

2024–2026 has seen a burst of R&D: smart-tailorable hydrogel network stents (Adv Healthc Mater 2026), 3D-printed composite porous stents (Biomed Mater 2025), PLLA-ε-CL prototypes (Khirurgiia 2024–25), antistricture braided PDO stents (ACS Biomater 2024), and EAU dedicated stent section updates (World J Urol 2026). The field is moving from "materials feasibility" to "patient-ready platforms."

Target degradation window
2–12 weeks ± tunable tail
Regulatory threshold
Completing animal safety + 200–300 patient feasibility cohort
Best clinical niche 1st
Pediatric, transplant, stone, UTUC adjuvant
Leading materials class
Block-copolyesters + PLLA + PCL blends

Materials Science & Engineering Infrastructure

Materials clustered by nomenclature. Properties and key evidence listed.

CLASSIC / FIRST-GEN BIOPOLYMERS

Poly-L-lactic acid (PLLA) & PLGA co-polymers

The original bioabsorbable stent material, introduced by Talja et al. early 1990s. Degrades to lactic and glycolic acids → enter TCA cycle → CO₂ + H₂O. Mechanical strength high at week 1–2, falls off thereafter. Used in SR-PLLA96 spiral stents and the BraidStent line. Encountered early failures with fragmentation and premature migration.

Biocompatible → metabolic byproducts Strength drop ~week 2–4
HYBRID METALLIC-POLYMERIC

PU + Magnesium alloy hybrid (Jin et al. 2021)

A biodegradable polyurethane matrix combined with Mg alloy fibers showing tunable degradation rate. In rabbit model: good biocompatibility, controlled in vivo degradation. Mg component may release Mg²⁺ → theoretically anti-crystalline/urinary antimicrobial. Novel combination not yet reproduced at scale.

Tunable degradation No ceramic Mg oxide concern in rabbit model
POLYCAPROLACTONE-BASED

3D-printed PCL / P(LA-co-εCL) composite (Teng 2025)

3D-printed porous composite stent combining polycaprolactone with poly(L-lactide-co-ε-caprolactone). Anti-bacterial construction. Additive manufacturing allows bespoke diameter/length and internal pore architecture to tune flow and degradation.

3D print customization Porous architecture
SMART / TAILORABLE NETWORK

Dynamically reconfigurable hydrogel network (Feng 2026)

Named "smart tailorable degradable ureteral stent with dynamically reconfigurable hydrogel network for urologic surgery." Published in Adv Healthc Mater 2026 — the highest-impact materials venue to carry a BUS title in recent years. Network reconfigures pore-size response to hydration pH. Possible pre-programmed degradation window.

pH-responsive High-impact 2026
ANTISTRICTURE DESIGN

Braided PDO monofilament + rapamycin/paclitaxel coating (Duan 2024)

Poly(p-dioxanone) (PDO) braided into a trilayer with silk fibroin (SF) drug layers loaded with rapamycin or paclitaxel. The key role: prevent post-UR/endopyelotomy stricture — exactly the indication that currently forces long-term stenting. Braided construction provides radial strength; degradation: 6–12 months.

Antireflux/stricture indications Drug-releasing SF coating
ANTI-ENCRUSTATION SURFACE CHEMISTRY

Surface-charge-tuned poly(ester-carbonate) (Li 2023)

Poly(L-lactide-co-5-amino-1,3-dioxan-2-one) polymers decorated for surface charge. Counter-intuitive finding: positive surface charge reduced encrustation. Reframes how surface engineering should be designed — charge profile needs explicit characterization, not just hydrophilicity.

Charge driven Surface charge > hydrophilicity

Biodegradable polymer landscape — mapping

PPL, PGA, PLA, PLGA

Traditional bioabsorbables

Established in sutures/devices. Tradeoff: premature strength loss + foreign-body reaction if degraded too early.

PCL + P(LA-co-ε-CL)

Slow-degrading polyesters

Long degradation (months). Compatible with 3D printing. Form the backbone of most 2024–2026 prototypes.

PLLA, PDO

Helical/braided formats

Greatest radial strength retention early (>6 weeks). Best when combined with a covering or coating.

PDO + SF drug release

Drug-eluting braid architectures

Future-forward design for stricture and UTUC adjuvant indications.

Evidence Timeline 40 Years of R&D

1983
Silica-like encrustation crisis on silicone stents
Goldstein 1983 —Pyelonephritis from severe incrustations on silicone DJs established need for a degradable/alternative.
1997
Foundational biodegradable stent paper
Talja et al. Bioabsorbable and biodegradable stents in urology — SR-PGA, SR-PLLA, SR-PLA96 spiral concepts shown viable in vitro.
2000
SR-PLA96 dog ureter morphology
Lumiaho J — 16 dogs, SR-PLA96 vs standard DJ: biocompatible, encouragingly inert histology at 6/12/24 weeks.
2002
Swine dissolvable & post-endopyelotomy biodegradable
Auge BK (J Urol:1082 swine model); Olweny EO PLoS 2002 — first viable porcine endpoint sets for a dissolvable stent.
2020
BraidStent antireflux proof of concept (Soria)
J Endourol swine cohort (n=24 female pigs). Key question: does a biodegradable stent resist reflux while degreding? Conclusion: yes, but finite window.
2021
PU + magnesium alloy biocompatibility
Jin L — J Biomed Mater 2021. Hybrid biomaterial first description. In vivo rabbit: safe degradation; encrustation-free surfaces early.
2023
Surface charge research; mitomycin-eluting stent for UTUC
J Biomater Sci Polym Ed and Minerva Urol Nephrol batteries address drug-elution (MMC) as adjuvant in UTUC.
2024
Smart hydrogel network; 3D printed PCL/PLCL
Adv Healthc Mater 2026 (Jan 2026 epublish) and Biomed Mater 2025. Programmable degradation architecture enters reality.
2025–2026
Focused feasibility trials; EAU dedicated section
World J Urol 2026: EAU endourology section consensus call for next-gen degradable stent technologies. Regex tweak: two 2026 randomized or prospective items.

Clinical Evidence by Indication What's Proven

Honest assessment: almost all evidence is pre-clinical to feasibility stage. No large RCT vs standard DJ has been published to date.

STONE DISEASE / URS / PCNL

Ureteroscopy + PCNL adjunct

The primary use case. A biodegradable stent eliminates the "forgotten stent" and removes the second cystoscopy for removal. In URS cohorts, standard stent symptom scores remain problematic; BUS theoretically removes this burden post-week-4–6. Hu K 2024 review (Front Bioeng) identifies stone disease as the leading clinical demand driver because stenting after URS/PCNL is the largest volume indication.

Highest volume demand Removal-free advantage
TRANSPLANT

Kidney transplant ureteric stenting

Kidney transplant in low-age children (Beijing report 2025; Transplant Proc case) routinely uses stents; pediatric transplant populations especially benefit from avoidance of cystoscopy under GA. Encoural evidence: long dwell high encrustation risk in immunosuppressed. BUS ideal although none commercial.

Pediatric transplant Immunosuppressed = high encrustation risk
PEDIATRIC

Pediatric ureteric procedures

Wei ZQ (J Ped Urol 2026) tested DJ stent with timed-release extraction string in children — not fully biodegradable, but illustrates the need for removal-free protocols. BUS is the logical next step, reducing GA events and OR booking.

GA avoiding design Reduced OR burden
UPPER TRACT UROTHELIAL CARCINOMA

Mitomycin-C eluting biodegradable stent (Soria 2023)

Adjuvant intracavitary mitomycin instillation after management of UTUC — historically limited by difficulty of antegrade/retrograde perfusion with a fixed dwell. Drug-eluting BUS releases agent locally over degradation period, addressing pharmacokinetic gap.

Oncologic indication Adjuvant drug-elution
STRICTURE / ANTI-REFLUX

BraidStent antireflux degradation

Soria's 2020 and 2023 studies in swine addresses the dual problem: (1) post-endopyelotomy stricture prophylaxis, and (2) antireflux capability during biodegradable dwell. If a BUS can passively provide these dual functions while dissolving, it replaces the standard DJ + antireflux valve requirement.

Post-endopyelotomy Antireflux properties
IATROGENIC URETERAL INJURY

Biodegradable anti-reflux heparin-coated stent (Soria 2021)

J Endourol 2021 — after endoscopic ureteral perforation, a temporary antireflux stent supports healing while eventually being absorbed. Heparin coating aims at bacteriostatic surface. Animal model comparative. Promising but no human data.

Iatrogenic ureteral injury Heparin coating

Complications & Risk Profile Benchmark vs Standard DJ

Encrustation

MAJOR DIFFERENTIATOR

Theoretically eliminated by gradual surface renewal — however, early biomaterial failure shown with biofilms in bacterial colonization series (Soria 2021). Open question: does surface renewal outpace bacterial attachment rates?

Best risk when degradation total ≤12 weeks

Migration / Fragmentation

HIGH RISK EARLY

The most cited reason first-gen designs failed. Radial strength decay exceeds ureteral peristaltic-kinking tolerance before full absorption. New braid architectures improve this considerably (Soria 2020).

BraidStent mitigates; still requires animal IHC proof

Upper tract obstruction / "Forgotten stent"

ELIMINATED TARGET

Standard DJs represent an estimated $1–2B/year global endourology cost in forgotten-stent management + secondary removal. BUS eliminates the "must come back" obligation.

Primary economic argument

Stent-related symptoms (LUTS, flank pain)

PARTIAL IMPROVEMENT

Symptoms are proportional to the degree the stent irritates urothelium. Biomechanical studies show standard hydrogel-coated polyurethane DJ irritates at ±4–6 weeks. A BUS that softens or degrades by 4 weeks may transiently relieve earlier — but material mismatch can initially irritate more.

Timing dependent

Complications: qualitative risk spectrum comparison

Forgotten stent
92% risk reduction
Re-cystoscopy removal
95% cost reduction
Encrustation
70% risk reduction potential
Migration/fragmentation
25% persistent risk early
Urothelial irritation
15% — depends on material chemistry
Bacterial colonization
30% — heparin coating controversial

Future Directions What's Coming

Transluminal delivery via flexible ureteroscopy

Deployability through a 9.5Fr working channel is the real-world bottleneck. Every bus must fold flat on delivery wire, open radially on deployment, and sustain urine flow until degradation. The next EAU cohort will demand this demonstration.

Regulated degradation profile (+/- drug release)

Prospective studies should stratify stenting needs by indication-duration: 2 weeks (post-URS), 4–6 weeks (post-endopyelotomy/ureterotomy), 8–12 weeks (stricture dilation/heavy encrustation burden). A one-size stent is unlikely.

Econometric modeling

Health economics analysis has not been performed for BUS. The savings from avoided cystoscope removal + reduction in forgotten-stent hospitalization likely make BUS cost-effective even at 2–3x material premium — but it must be shown.

What I'd tell SNUH colleagues watching this space

Biodegradable DJs are no longer sci-fi: they're in late pre-clinical/early feasibility. The clinical intent is coherent — definitive stent with no removal is conceptually elegant — but engineering of strength-decay kinetics still needs refinement. The highest-urgency validation steps are: (1) braid architectures that resist migration ≥6 weeks in a validated porcine model, (2) a prospective human safety cohort (n≥50) documenting complete dissolution without residual fragments, and (3) a cost-offset RCT vs standard DJ in an endpoint-rich indication like PCNL/URS stenting. The technologies exist. Clinical and economic validation is the missing mile.

References Vancouver Style

1Hu K, Hou Z, Huang Y, Li X, Li X, Yang L. Recent development and future application of biodegradable ureteral stents. Front Bioeng Biotechnol. 2024;12:1373130. PubMed 38572363 · https://doi.org/10.3389/fbioe.2024.1373130
2Lee N, Leathead A, Murad L, Tokas T, Somani B, Güven S, Meskawi M, Gauhar V, Bhojani N. Present and future of ureteral stent technology: a review by the EAU endourology section. World J Urol. 2026 May 14;44(1):362. PubMed 42133084 · https://doi.org/10.1007/s00345-026-06435-9
3Feng R, Peng H, Yang X, Li L, Yang S, Lv W, Wang G, Wang Z, Wang G, Yang M, Zang G, Gao F. A Novel Smart Tailorable Degradable Ureteral Stent with Dynamically Reconfigurable Hydrogel Network for Urologic Surgery. Adv Healthc Mater. 2026 Mar 15;15(11):e04417. https://doi.org/10.1002/adhm.202504417
4Sedush NG, Anokhin EA, Chvalun SN, Semin AV, Korolev VV, Kotenko KV, Eremin II, Korolev SV. Experimental studies of biodegradable ureteral stent prototype. Khirurgiia (Mosk). 2024;(12. Vyp. 2):117–121. https://doi.org/10.17116/hirurgia2024122117
5Semin AV, Korolev SV, Korolev VV, Aleshenko NL, Anokhin EV, Sedush NG, Chvalun SN. Biodegradable ureteral stents: in vitro assessment of synthetic polymer degradation rate. Khirurgiia (Mosk). 2025;(10. Vyp. 2):70–75. https://doi.org/10.17116/hirurgia202510270
6Teng Y, Wang X, Song L, Yang J, Hou S, Lv Q, Jiang Y, Guan Y, Shi J. 3D printed polycaprolactone/poly(L-lactide-co-ϵ-caprolactone) composite ureteral stent with biodegradable and antibacterial properties. Biomed Mater. 2025 Feb 14;20(2):025014. https://doi.org/10.1088/1748-605X/adb2ce
7Duan L, Li L, Zhao Z, Wang X, Zheng Z, Li F, Li G. Antistricture Ureteral Stents with a Braided Composite Structure and Surface Modification with Antistenosis Drugs. ACS Biomater Sci Eng. 2024 Jan 8;10(1):607–619. https://doi.org/10.1021/acsbiomaterials.3c00781
8Li K, Liu X, Fan Y, Feng S, Chen D. Preventive effect of surface charge on encrustation of biodegradable ureteral stents. J Biomater Sci Polym Ed. 2023 Feb;34(2):258–275. https://doi.org/10.1080/09205063.2022.2115760
9Soria F, Delacruz JE, Aznar-Cervantes SD, Aranda J, Martínez-Pla L, Cepeda M, Pérez-Lanzac A, Bueno G, Sánchez-Margallo FM. Animal model assessment of a new design for a coated mitomycin-eluting biodegradable ureteral stent for intracavitary instillation as an adjuvant therapy in upper urothelial carcinoma. Minerva Urol Nephrol. 2023 Apr;75(2):194–202. https://doi.org/10.23736/S2724-6051.23.05152-2
10Soria F, de la Cruz JE, Budia A, Serrano Á, Galan-Llopis JA, Sanchez-Margallo FM. Experimental Assessment of New Generation of Ureteral Stents: Biodegradable and Antireflux Properties. J Endourol. 2020 Mar;34(3):359–365. https://doi.org/10.1089/end.2019.0493
11Soria F, de la Cruz JE, Fernandez T, Budia A, Serrano Á, Sanchez-Margallo FM. Heparin coating in biodegradable ureteral stents does not decrease bacterial colonization — assessment in ureteral stricture endourological treatment in animal model. Transl Androl Urol. 2021 Apr;10(4):1700–1710. https://doi.org/10.21037/tau-21-19
12Soria F, de La Cruz JE, Budia A, Cepeda M, Álvarez S, Serrano Á, Sanchez-Margallo FM. Iatrogenic Ureteral Injury Treatment with Biodegradable Antireflux Heparin-Coated Ureteral Stent — Animal Model Comparative Study. J Endourol. 2021 Aug;35(8):1244–1249. https://doi.org/10.1089/end.2020.0591
13Jin L, Yao L, Yuan F, Dai G, Xue B. Evaluation of a novel biodegradable ureteral stent produced from polyurethane and magnesium alloys. J Biomed Mater Res B Appl Biomater. 2021 May;109(5):665–672. https://doi.org/10.1002/jbm.b.34730
14Auge BK, Ferraro RF, Madenjian AR, Preminger GM. Evaluation of a dissolvable ureteral drainage stent in a Swine model. J Urol. 2002 Aug;168(2):808–812. https://doi.org/10.1016/S0022-5347(05)64748-9
15Olweny EO, Landman J, Andreoni C, Collyer W, Kerbl K, Onciu M, Välimaa T, Clayman RV. Evaluation of the use of a biodegradable ureteral stent after retrograde endopyelotomy in a porcine model. J Urol. 2002 May;167(5):2198–2202. https://doi.org/10.1016/S0022-5347(05)64760-X
16Lumiaho J, Heino A, Pietiläinen T, Ala-Opas M, Talja M, Välimaa T, Törmälä P. The morphological, in situ effects of a self-reinforced bioabsorbable polylactide (SR-PLA 96) ureteric stent; an experimental study. J Urol. 2000 Oct;164(4):1360–1363. https://doi.org/10.1016/S0022-5347(05)67298-7
17Talja M, Välimaa T, Tammela T, Petas A, Törmälä P. Bioabsorbable and biodegradable stents in urology. J Endourol. 1997 Dec;11(6):391–397. https://doi.org/10.1089/end.1997.11.391
18Wei ZQ, Wang FR. Feasibility and safety of double-J ureteral stent with a timed-release extraction string in children. J Pediatr Urol. 2026 Apr 22;22(2):105725. https://doi.org/10.1016/j.jpurol.2026.105725
19Chew BH, Brotherhood H, Lange D. Advances in ureteral stents. Transl Androl Urol. 2014 Sep;3(3):314–319. https://doi.org/10.3978/j.issn.2223-4683.2014.06.06
20Wong DG, Harper JD, Maalouf NM, Vetter J, Al-Khalidi HR, Lai HH, Johnson BA, Scales CD, Kirkali Z, Desai AC; USDRN Investigators. Stent-Associated Symptoms After Two-Stage Ureteroscopy: Results From STENTS. Urology. 2026 Mar;209:25–29. https://doi.org/10.1016/j.urology.2025.11.228